Skip to main content
CE
NYSE Industrial Applications And Services

Celanese Reports Q2 2026 Adjusted EPS of $2.45, Highest in Nearly Three Years; Guides Q3 EPS $1.35-$1.75, Full-Year ~$6.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Chemical Stocks · Materials
Sentiment info
Positive
Importance info
8
Price
$44.3
Mkt Cap
$4.961B
52W Low
$35.13
52W High
$70.7
52W Position info
26% above low
Off High info
37% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

CE sits 26% above its 52-week low of $35.13 on elevated volume (2.0× avg).

Summary

Celanese reported Q2 2026 adjusted EPS of $2.45, beating estimates, and guided Q3 EPS of $1.35-$1.75 and full-year ~$6.00. Strong segment performance and free cash flow generation support the company's deleveraging strategy.


Key Events · Earnings and Guidance · CE

  • Q2 2026 Earnings Beat

    Adjusted EPS of $2.45 exceeded consensus by $0.22, the highest in nearly three years, driven by strong commercial execution in both Engineered Materials and the Acetyl Chain.

  • Segment Performance Highlights

    Engineered Materials posted record variable margin with adjusted EBIT of $234 million; Acetyl Chain delivered $321 million in adjusted EBIT, leveraging Western Hemisphere supply advantages.

  • Q3 and Full-Year Guidance

    Q3 2026 adjusted EPS guidance of $1.35-$1.75 reflects normalization of supply-related tailwinds and higher raw material costs; full-year 2026 adjusted EPS guidance maintained at approximately $6.00.

  • Free Cash Flow and Deleveraging

    Generated $140 million in free cash flow in Q2; full-year free cash flow target of $700-$800 million reaffirmed, supporting significant expected improvement in net debt-to-operating EBITDA ratio by year-end 2026.


Analysis · CE · Industrial Applications And Services

Celanese delivered its strongest quarterly earnings in nearly three years, with adjusted EPS of $2.45 beating consensus by $0.22. Both business segments posted robust results: Engineered Materials achieved its highest-ever variable margin, driven by growth in medical and electronics, while the Acetyl Chain capitalized on supply disruptions to capture value in the Western Hemisphere. The company generated $140 million in free cash flow and reaffirmed its full-year free cash flow target of $700-$800 million, supporting its deleveraging plan. Q3 guidance of $1.35-$1.75 reflects expected normalization of supply-related opportunities and higher raw material costs, but full-year EPS guidance of ~$6.00 signals confidence in sustained earnings power. The results and outlook reinforce the company's ability to generate cash and reduce debt, a critical focus given its high leverage and recent covenant amendment.

At the time of this filing, CE was trading at $44.30 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5B. The 52-week trading range was $35.13 to $70.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CE - Latest Insights

CE
Aug 04, 2026, 4:27 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $44.20
Real-time Price: $45.75 info
Change: +$1.55 (+4%) info
Market Cap: $4.961B info
CE
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $43.31
Real-time Price: $45.75 info
Change: +$2.44 (+6%) info
Market Cap: $4.961B info
CE
Jul 30, 2026, 6:30 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $44.24
Real-time Price: $45.75 info
Change: +$1.51 (+3%) info
Market Cap: $4.961B info
CE
Jun 10, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $50.55
Real-time Price: $45.75 info
Change: -$4.80 (-9%) info
Market Cap: $4.961B info
CE
Jun 04, 2026, 5:35 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $53.35
Real-time Price: $45.75 info
Change: -$7.60 (-14%) info
Market Cap: $4.961B info